ACTA1 and chronic kidney disease: Similar results were also observed in comparison with other commonly used CKD medications, such as RAAS blockers valsartan (Val) or enalapril (Ena),[20] in particular in reducing α‐SMA and ECM expression (Figure S2A, Supporting Information).